Georgina Buck
Impact in
- Hematology top 0.2%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 27
- Chronic Myeloid Leukemia Treatments 20
- Acute Myeloid Leukemia Research 11
- Genetics 17
- Myeloproliferative Neoplasms: Diagnosis and Treatment 12
- Chronic Lymphocytic Leukemia Research 5
- Co-authors
- Colin BaigentAnthony KeechPatricia M. KearneyC PollicinoT. SourjinaLisa BlackwellAdrienne KirbyR Peto
- Journals
- Blood (22 papers)British Journal of Haematology (5 papers)Journal of Clinical Oncology (4 papers)European Heart Journal (4 papers)American Heart Journal (2 papers)
- Partner nations
- United KingdomUnited StatesIsrael
In The Last Decade
Georgina Buck
53 papers receiving 9.6k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Hematology 3.2k
- Genetics 2.1k
- Endocrinology, Diabetes and Metabolism 1.6k
- Public Health, Environmental and Occupational Health 2.8k
- Surgery 3.6k
Countries citing papers authored by Georgina Buck
This map shows the geographic impact of Georgina Buck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georgina Buck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georgina Buck more than expected).
Fields of papers citing papers by Georgina Buck
This network shows the impact of papers produced by Georgina Buck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georgina Buck. The network helps show where Georgina Buck may publish in the future.
Co-authors
The 25 scholars most cited alongside Georgina Buck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 8 | |
| 4 | 2023 | 3 | |
| 5 | 2023 | 3 | |
| 6 | 2018 | 21 | |
| 7 | 2018 | 49 | |
| 8 | 2017 | 0 | |
| 9 | 2017 | 26 | |
| 10 | 2017 | 0 | |
| 11 | 2013 | 21 | |
| 12 | Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised controlled trials of statins (vol 366, pg 1267, 2005) | 2008 | 9 |
| 13 | In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993) Hit paper breakdown → | 2007 | 537 |
| 14 | Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial Hit paper breakdown → | 2006 | 502 |
| 15 | Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study Hit paper breakdown → | 2006 | 591 |
| 16 | ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. | 2005 | 5 |
| 17 | Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Hit paper breakdown → | 2005 | 4980 |
| 18 | 2005 | 473 | |
| 19 | The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. | 2003 | 9 |
| 20 | Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 trial. | 2003 | 1 |
About Georgina Buck
Georgina Buck is a scholar working on Hematology, Genetics, Public Health, Environmental and Occupational Health, Biochemistry and Pediatrics, Perinatology and Child Health, having authored 56 papers that have together received 10.0k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (25 papers), Chronic Myeloid Leukemia Treatments (20 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers), Acute Myeloid Leukemia Research (11 papers), Kruppel-like factors research (8 papers), Childhood Cancer Survivors' Quality of Life (8 papers), Antiplatelet Therapy and Cardiovascular Diseases (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Hematology (3.2k citations), Genetics (2.1k citations), Endocrinology, Diabetes and Metabolism (1.6k citations), Public Health, Environmental and Occupational Health (2.8k citations) and Surgery (3.6k citations). Georgina Buck has collaborated with scholars based in United Kingdom, United States and Israel. Frequent co-authors include Colin Baigent, Anthony Keech, Patricia M. Kearney, C Pollicino, T. Sourjina, Lisa Blackwell, Adrienne Kirby, R Peto, Ruth Collins and Anthony H. Goldstone. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, European Heart Journal and American Heart Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.